NPRL2、Survivin在肝细胞肝癌中的表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2014.617

摘要/Abstract

摘要： 目的探究NPRL2、Survivin在肝细胞肝癌中的作用,两者间的关系及其与各临床指标间的联系。方法收集45例肝细胞肝癌患者的癌组织、癌旁组织及15例正常肝脏组织,采用免疫组织化学方法、实时荧光定量RT-PCR法检测NPRL2、Survivin在各组织中的表达。结果 NPRL2在肝癌组织中的表达低于其癌旁组织、正常肝脏组织(P<0.01),与肿瘤TNM分期有关(P<0.05)。Survivin在肝癌组织中的表达高于癌旁组织、正常肝脏组织(P<0.01),且与血清AFP浓度、TNM分期有关(P<0.05)。在正常肝脏组织和癌旁组织中,NPRL2、Survivin的表达差异无统计学意义(P>0.05)。Spearman等级相关分析结果表明,NPRL2、Survivin mRNA在肝癌组织中的表达呈负相关(r=-0.45, P<0.01)。结论在肝细胞肝癌中,NPRL2是肿瘤抑制基因,Survivin是癌基因,且两者表达呈负相关,共同参与了肿瘤的发生发展。

关键词: RT-PCR, Survivin, NPRL2, 肝细胞肝癌, 免疫组织化学

Abstract: Objective To investigate the expressions of NPRL2 and Survivin, and their association with the clinicopathologic parameters of hepatocellular carcinoma (HCC). Methods A total of 45 HCC tissues, paracancerous liver tissues and 15 normal liver tissues were collected. Expressions of NPRL2 and Survivin were determined with immunohistochemistry and RT-PCR methods. Results Compared with paracancerous liver tissues and normal liver tissues, HCC tissues had higher Survivin expression but lower NPRL2 expression (P<0.01), but no significant differences were found between paracancerous liver tissues and normal liver tissues (P>0.05). NPRL2 expression was significantly related to TNM stage (P<0.05). Survivin expression was associated with serum AFP concentration and TNM stage (P<0.05). By spearman relative analysis, there was significant correlation between NPRL2 mRNA and Survivin mRNA (r=-0.45, P<0.01). Conclusion In hepatocellular carcinoma, anti-oncogene NPRL2 was negatively related to oncogene Survivin. The two genes may play important roles in the occurrence and development of hepatocellular carcinoma.

Key words: NPRL2, Survivin, Immunohistochemistry, RT-PCR, Hepatocellular carcinoma

中图分类号:

R735.7

谷旭, 王夏青, 任万华, 秦成勇, 韩国庆. NPRL2、Survivin在肝细胞肝癌中的表达及其临床意义[J]. 山东大学学报（医学版）, 2015, 53(6): 68-72.

GU Xu, WANG Xiaqing, REN Wanhua, QIN Chengyong, HAN Guoqing. Expression and clinical significance of NPRL2 and Survivin in hepatocellular carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 68-72.

参考文献

[1] 陈万青, 张思维,郑荣寿, 等. 中国2009年恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2013, 22(1): 10-21. CHEN Wanqing, ZHANG Siwei, ZHENG Rongshou, et al. Report of cancer incidence and mortality in China, 2009[J]. China Cancer, 2013, 22(1): 10-21.
[2] Aravalli RN, Cressman EN, Steer CJ, et al. Cellular and molecular mechanisms of hepatocellular carcinoma: an update[J]. Arch Toxicol, 2013, 87(2): 227-247.
[3] Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium[J]. Cancer Res, 2000, 60(21): 6116-6133.
[4] Zabarovsky ER, Lerman MI, Minna JD, et al. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers[J]. Oncogene, 2002, 21(45): 6915-6935.
[5] Liu AY, Liu DG, Du YJ, et al. Relationship between tumor and peripheral blood NPRL2 mRNA levels in patients with colorectal adenoma and colorectal cancer[J]. Cancer Biol Ther, 2014, 15(5): 489-495.
[6] Ambrosini G, Adida C, Altieri DC, et al. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997, 3(8): 917-921.
[7] Kanwar JR, Kamalapuram SK, Kanwar RK, et al. Survivin signaling in clinical oncology: a multifaceted dragon[J]. Med Res Rev, 2013, 33(4): 765-789.
[8] Li T, Wang G. Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities[J]. Int J Mol Sci, 2014, 15(10):18856-18891.
[9] Kurata A, Katayama R, Watanabe T, et al. TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling[J]. Cancer Sci, 2008, 99(9): 1827-1834.
[10] Kanwar JR, Kamalapuram SK, Kanwar RK, et al. Targeting Survivin in cancer: the cell-signalling perspective[J]. Drug Discov Today, 2011, 16(11-12): 485-494.
[11] Li J, Wang F, Haraldson K, et al. Functional characterization of the candidate tumor suppressor gene NPRL2 /G21 located in 3p21.3C[J]. Cancer Res, 2004, 64(18):6438-6443.
[12] Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects[J]. Exp Lung Res, 2007, 33(6): 289-301.
[13] Economidou F, Tzortzaki EG, Schiza S, et al. Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions[J]. Oncol Rep, 2007, 18(6): 1507-1512.
[14] Otani S, Takeda S, Yamada S, et al. The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor[J]. Journal of Surgical Oncology, 2009, 100(5): 358-363.
[15] Ueda K, Kawashima H, Ohtani S, et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells[J]. Cancer Res, 2006, 66(19): 9682-9690.
[16] Jin Y, Chen J, Feng Z, et al. The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma[J]. Tumour Biol, 2014, 35(10): 9905-9910.
[17] Selemetjev S, Dencic TI, Marecko I, et al. Evaluation of Survivin expression and its prognostic value in papillary thyroid carcinoma[J]. Pathol Res Pract, 2014, 210(1): 30-34.
[18] Sun PL, Jin Y, Kim H, et al. Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma[J]. Virchows Arch, 2013, 463(3): 427-436.
[19] Garcia-Saez I, Lacroix FB, Blot D, et al. Structural characterization of HBXIP: the protein that interacts with the anti-apoptotic protein Survivin and the oncogenic viral protein HBx[J]. J Mol Biol, 2011, 405(2): 331-340.
[20] Dieterle AM, Böhler P, Keppeler H, et al. PDK1 controls upstream PI3K expression and PIP3 generation[J]. Oncogene, 2014, 33(23): 3043-3053.
[21] Serrano-López J, Serrano J, Figueroa V, et al. Cytoplasmic localization of wild-type Survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia[J]. Haematologica, 2013, 98(12): 1877-1885.

相关文章 15

[1]	黄方康瑞吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[2]	王琳琳孙美丽孙玉萍张楠刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[3]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[4]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[5]	吴霖,石晨曦,童星. 肺良性转移性平滑肌瘤病7例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(4): 78-84.
[6]	樊荣,李彬彬,马晓丽,汪运山,郏雁飞. 胃癌中DEC2、HIF-2α的表达及临床意义[J]. 山东大学学报 (医学版), 2023, 61(7): 12-18.
[7]	靳新娟,左立平,邓展昊,李安宁,于德新. MRI影像组学对135例肝癌耐药蛋白PFKFB3的预测价值[J]. 山东大学学报 (医学版), 2023, 61(6): 79-86.
[8]	左立平,蒋丰洋,周斌彬,范金蕾,梁永锋,邓展昊,于德新. 术前MRI在预测169例肝细胞肝癌微血管侵犯及早期复发的价值[J]. 山东大学学报 (医学版), 2022, 60(3): 89-95.
[9]	董宏杰,张俊梅,王帅,王宏伟,张坤迪,胡玮,谢晓鸿,谢时灵,谷立川. 新型冠状病毒混合样品检测研究[J]. 山东大学学报 (医学版), 2021, 59(4): 1-5.
[10]	柴佳威,朱坤兵,张华伟,崔凤云,王甜甜,田兴松. 1例肝细胞肝癌甲状腺转移罕见病例报道与文献回顾[J]. 山东大学学报 (医学版), 2021, 59(3): 120-124.
[11]	赵怀龙,吕燕,赵红,赵宝添,韩莹,杨国樑,王春荣,关恒云,刘辉,刘岚铮. 济南市47例新型冠状病毒肺炎患者取样部位对核酸检测结果的影响[J]. 山东大学学报 (医学版), 2020, 58(4): 28-31.
[12]	王宝金,赵欣欣,李霞,马倩,王新月,孙阳,史中娜. miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭[J]. 山东大学学报 (医学版), 2020, 58(12): 23-28.
[13]	邵倩倩,王景溥,王庆杰. 抗凋亡转录因子在肝细胞肝癌中的表达及预后作用[J]. 山东大学学报 (医学版), 2018, 56(12): 7-12.
[14]	聂思月,王震,孙靖宇,刘杰,李娟,魏小娟,路春晓,吕兴龑,王淑云,孙玉萍. ANGPTL5在人胃癌组织中的表达及临床意义[J]. 山东大学学报（医学版）, 2017, 55(8): 61-65.
[15]	王永强,张维全,孙启峰,董晓鹏,彭传亮,张媛,赵小刚. 细胞角蛋白14基因在非小细胞肺癌中的表达与意义[J]. 山东大学学报（医学版）, 2017, 55(3): 83-87.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed